Omega Fund Management has reduced its stake in Kestra Medical Technologies (KMTS) by 351,442 shares, translating to approximately $8.28 million based on average quarterly pricing, according to a recent SEC filing. Following this sale, Omega holds 1,022,149 shares, valued at $20.37 million, which now represents 12.5% of its reportable assets under management.
This divestment comes amid Kestra’s impressive revenue growth, with a reported third-quarter revenue of $24.6 million—up 63% year-over-year—and an increase in full-year revenue guidance to $93 million, indicating a potential 55% annual growth. However, the stock has underperformed, trailing the S&P 500 by 29 percentage points, highlighting a disconnect between financial performance and market perception. Despite the cut, Omega’s substantial remaining stake suggests ongoing confidence in Kestra’s long-term growth potential.
Investors should monitor Kestra’s ability to balance aggressive expansion with profitability, as its substantial cash position may provide the leverage needed to improve market sentiment moving forward.
Source: fool.com